OR WAIT null SECS
July 21, 2021
Pall has secured a manufacturing contract with Exothera for the suspension-based manufacture of gene therapies and viral vector-based vaccines.
July 19, 2021
Modeling the manufacturing process benefits both development and operations.
July 16, 2021
MTBVAC has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.
ImmunityBio will proceed with a Phase I/II/III trial in South Africa of their dual-antigen T-cell vaccine as a boost in participants who were previously vaccinated against COVID-19.
The US federal government awarded new funding to the National Institute for Innovation in Manufacturing Biopharmaceuticals, including funding under the American Rescue Plan that will be used to advance vaccine manufacturing.
July 09, 2021
Univercells Technologies and VectorBuilder to produce custom viral vectors for cell and gene therapies as well as vaccine applications.
July 03, 2021
Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.
June 18, 2021
The US government will invest $3 billion from the American Rescue Plan into a COVID-19 antiviral development strategy.
June 17, 2021
Sanofi’s new Pennsylvania facility expands production of Fluzone High-Dose Quadrivalent flu vaccine.
June 08, 2021
The vaccine is now authorized for ages 12 and older in European Union member states and the UK.